{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:44:34Z","timestamp":1777877074133,"version":"3.51.4"},"reference-count":0,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100020292","name":"Pacira BioSciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>What is this summary about?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>This plain language summary of publications outlines 2 publications that represent 2 separate analyses of a single study of triamcinolone acetonide extended-release (TA-ER). TA-ER is an injection into the knee joint approved to treat osteoarthritis knee pain. The study compared the effects of TA-ER versus a standard form of the steroid triamcinolone acetonide (called triamcinolone acetonide crystalline suspension [TAcs]) on blood glucose levels in participants with knee osteoarthritis and type 2 diabetes.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>What were the main results?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Participants with knee osteoarthritis and type 2 diabetes who received an injection of TA-ER had smaller increases in blood glucose levels than participants who received TAcs, especially in the first 3 days after injection. TA-ER also caused fewer spikes in blood glucose levels in participants compared with TAcs. No serious side effects were reported for either TA-ER or TAcs.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>What do the results mean?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>These results are important because there is an unmet need for effective pain relief options for people with knee osteoarthritis who also have type 2 diabetes. Standard steroid treatments can raise blood glucose levels, making them potentially problematic for this group.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Who might find this summary helpful?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>The purpose of this plain language summary of publications is to provide information from recent research to people with knee osteoarthritis and type 2 diabetes who may require an injection into the knee joint or who may receive an injection of TA-ER for treatment of knee osteoarthritis. It is also intended to help healthcare professionals understand findings from recent research, supporting TA-ER as potentially more favorable versus standard steroids for patients with both knee osteoarthritis and type 2 diabetes.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Who should read this summary?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>People who may find this summary helpful are those living with knee osteoarthritis and type 2 diabetes and their families, patient advocates, patient groups, and the healthcare professionals who treat them.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Who sponsored this study?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Pacira BioSciences, Inc. (formerly Flexion Therapeutics; telephone number: 844-353-9466) sponsored this study.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>When was this plain language summary of publications written?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>This summary was drafted in April-May 2025.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Disclaimers<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\u25cf\u2003TA-ER is approved to treat osteoarthritis knee pain.<\/jats:p>\n                  <jats:p>\u25cf\u2003Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe to patients.<\/jats:p>\n                  <jats:p>\u25cf\u2003This plain language summary of publications outlines 2 publications based on separate analyses of a single study. The results of that single study may be different from results of other studies.<\/jats:p>","DOI":"10.1177\/1759720x261433612","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:22:36Z","timestamp":1775780556000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 Diabetes"],"prefix":"10.1177","volume":"18","author":[{"given":"Andrew I.","family":"Spitzer","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Rodbard","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Consultants, Rockville, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,9]]},"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261433612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X261433612","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261433612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:40:40Z","timestamp":1777588840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X261433612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":0,"alternative-id":["10.1177\/1759720X261433612"],"URL":"https:\/\/doi.org\/10.1177\/1759720x261433612","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"1759720X261433612"}}